Geoffrey Kumwenda

Geoffrey Kumwenda

Auto-generated profile, based on publicly available information

Geoffrey Kumwenda

Division of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke City, Tochigi, 329-0498, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
FLFeng-Yu Li
Feng-Yu Li
XTXin-Ee Tan
Xin-Ee Tan
YSYuzuki Shimamori
Yuzuki Shimamori
KKKotaro Kiga
Kotaro Kiga
SVSrivani Veeranarayanan
Srivani Veeranarayanan
Longzhu CuiLongzhu Cui
Longzhu Cui
In response to the escalating antibiotic resistance in multidrug-resistant pathogens, we propose an innovative phagemid-based capsid system to generate CRISPR-Cas13a-loaded antibacterial capsids (AB-capsids) for targeted therapy against multidrug-resistant Staphylococcus aureus. Our optimized phagemid system maximizes AB-capsid yield and purity, showing a positive correlation with phagemid copy number. Notably, an 8.65-fold increase in copy number results in a 2.54-fold rise in AB-capsid generation. Phagemids carrying terL-terS-rinA-rinB (prophage-encoded packaging site genes) consistently exhibit high packaging efficiency, and the generation of AB-capsids using lysogenized hosts with terL-terS deletion resulted in comparatively lower level of wild-type phage contamination, with minimal compromise on AB-capsid yield. These generated AB-capsids selectively eliminate S. aureus strains carrying the target gene while sparing non-target strains. In conclusion, our phagemid-based capsid system stands as a promising avenue for developing sequence-specific bactericidal agents, offering a streamlined approach to combat antibiotic-resistant pathogens within the constraints of efficient production and targeted efficacy.

1 December 2019 in Journal of Medical Microbiology
Verified
Journal Article
Open access
GKGeoffrey P. Kumwenda
Geoffrey P. Kumwenda
YSYo Sugawara
Yo Sugawara
RARyuichiro Abe
Ryuichiro Abe
YAYukihiro Akeda
Yukihiro Akeda
WKWatipaso Kasambara
Watipaso Kasambara
SHShigeyuki Hamada
Shigeyuki Hamada
Purpose. Carbapenemase-producing Enterobacteriaceae (CPE) have become a global concern and a serious threat to human health due to their resistance to multiple antibiotics. In this study, we identified and characterized CPE for the first time in Malawi, southeastern Africa. Methodology. We investigated the possible presence of carbapenemases among a collection of 200 ceftriaxone-nonsusceptible Gram-negative clinical isolates obtained from five Malawian hospitals between January 2016 and December 2017, using both phenotypic and genotypic tests. Molecular typing of CPE was done by PFGE, multilocus sequence typing (ST) or phylogenetic grouping. Resistant plasmids were characterized by S1 PFGE, Southern blotting and conjugation assays. Results. Out of 200 isolates, we detected 16 (8 %) CPE of which all originated from one referral hospital, Kamuzu Central Hospital, in the Central part of Malawi. Of 16 isolates, seven Klebsiella pneumoniae ST340/CC258 carried bla KPC-2, two Escherichia coli ST636 (phylogroup B2) carried bla NDM-5, six E. coli ST617 (phylogroup A) and one Klebsiella variicola carried bla OXA-48. All carbapenemases were plasmid-encoded, but only bla NDM-5-carrying plasmids could be conjugated. Most isolates co-harboured other β-lactamases and consequently exhibited a wider spectrum of resistance to commonly used antibiotics. We observed indistinguishable genetic profiles between strain types, despite originating from different wards, suggesting acquisition during admission and intra-hospital spread. Conclusion. This report strongly suggests a probable existence of highly resistant various types of CPE organisms in Malawi including KPC-2-producing K. pneumoniae ST340/CC258, a known high-risk epidemic lineage.

1 June 2020 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
RARyuichiro Abe
Ryuichiro Abe
YAYukihiro Akeda
Yukihiro Akeda
NSNoriko Sakamoto
Noriko Sakamoto
GKGeoffrey Kumwenda
Geoffrey Kumwenda
YSYo Sugawara
Yo Sugawara
SHShigeyuki Hamada
Shigeyuki Hamada
To analyse plasmids carrying blaIMP-6 in isolates of Klebsiella pneumoniae obtained from multicentre carbapenem-resistant Enterobacteriaceae surveillance. We characterised plasmids harbouring blaIMP-6 by the whole-genome sequencing of four K. pneumoniae isolates carrying blaIMP-6, and compared them with the pKPI-6 plasmid widespread in western Japan through PFGE, Southern blotting, bacterial conjugation, and qPCR. Whole-genome sequencing analysis revealed that three of the four isolates carried approximately 50 kbp plasmids similar to the pKPI-6 plasmid, however, one isolate carried a 250 kbp plasmid harbouring blaIMP-6 (pE196_IMP6). So far, all of the reported plasmids carrying blaIMP-6 were similar to the pKPI-6 plasmid, and this plasmid was a novel blaIMP6-carrier. The size and transferability of this plasmid was confirmed by Southern hybridisation and conjugation experiments. We demonstrated that the generation of plasmid pE196_IMP6 was due to an intramolecular transposition mediated by IS26, and a homologous recombination between plasmids pKPI-6 and pE013 that was obtained from another carbapenem-resistant Enterobacteriaceae isolate in this analysis. As a result of co-integration with pE013, pE196_IMP6 acquired six additional pairs of type II toxin-antitoxin systems that pKPI-6 does not carry. Transcription of all of the toxin-antitoxin systems were confirmed in an isolate carrying pE196_IMP6 by qPCR. We detected a novel plasmid carrying blaIMP-6, and revealed the origin of this plasmid. Toxin-antitoxin system acquisition could enable pE196_IMP6 maintenance persistently through successions, even without selection pressure by the clinical usage of antimicrobials, generating broad dissemination and longer carbapenem-resistant Enterobacteriaceae colonisation duration in patients.